Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?

Creative Commons License

Besiroglu M., Demir T., Shbair A. T. M., Yasin A. I., Topcu A., Turk H. M.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, vol.31, pp.932-936, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31
  • Publication Date: 2021
  • Doi Number: 10.29271/jcpsp.2021.08.932
  • Journal Name: Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.932-936
  • Keywords: Bevacizumab, Duration of treatment, Glioblastoma multiforme, Predictive score, Temozolomide, MALIGNANT GLIOMAS, MARKERS
  • Bezmialem Vakıf University Affiliated: Yes


Objective: To evaluate the predictive significance of the duration of temozolomide (TMZ) in patients with glioblastoma multiforme (GBM) who were treated with bevacizumab (Beva) as second-line setting.